Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] traded at a low on 2025-08-22, posting a -2.74 loss after which it closed the day’ session at $0.06.
The results of the trading session contributed to over 25687664 shares changing hands. Over the past one week, the price volatility of Adaptimmune Therapeutics Plc ADR stands at 18.34% while the volatility over the past one month is 18.28%.
The market cap for ADAP stock reached $15.08 million, with 265.05 million shares outstanding and 255.41 million shares in the current float. Compared to the average trading volume of 28.30M shares, ADAP reached a trading volume of 25687664 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Adaptimmune Therapeutics Plc ADR [ADAP]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADAP shares is $0.35 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADAP stock is a recommendation set at 3.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Adaptimmune Therapeutics Plc ADR shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 29, 2025. The new note on the price target was released on June 26, 2025, representing the official price target for Adaptimmune Therapeutics Plc ADR stock. Previously, the target price had yet another raise to $4, while H.C. Wainwright analysts kept a Buy rating on ADAP stock.
How has ADAP stock performed recently?
Adaptimmune Therapeutics Plc ADR [ADAP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.37. With this latest performance, ADAP shares dropped by -82.88% in over the last four-week period, additionally sinking by -89.83% over the last 6 months – not to mention a drop of -89.44% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADAP stock in for the last two-week period is set at 29.39, with the RSI for the last a single of trading hit 0.0160, and the three-weeks RSI is set at 0.0207 for Adaptimmune Therapeutics Plc ADR [ADAP]. The present Moving Average for the last 50 days of trading for this stock 0.1896, while it was recorded at 0.0609 for the last single week of trading, and 0.4038 for the last 200 days.
Adaptimmune Therapeutics Plc ADR [ADAP]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Adaptimmune Therapeutics Plc ADR [ADAP] shares currently have an operating margin of -236.46% and a Gross Margin at 78.45%. Adaptimmune Therapeutics Plc ADR’s Net Margin is presently recorded at -258.57%.
Adaptimmune Therapeutics Plc ADR (ADAP) Capital Structure & Debt Analysis
Adaptimmune Therapeutics Plc ADR (ADAP) Efficiency & Liquidity Metrics
Adaptimmune Therapeutics Plc ADR (ADAP) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Adaptimmune Therapeutics Plc ADR. (ADAP) effectively leverages its workforce, generating an average of -$335553.36 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.52% and a Quick Ratio of 1.29%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Adaptimmune Therapeutics Plc ADR [ADAP]
With the latest financial reports released by the company, Adaptimmune Therapeutics Plc ADR posted -0.01/share EPS, while the average EPS was predicted by analysts to be reported at -0.18/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.17. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADAP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adaptimmune Therapeutics Plc ADR go to -6.27%.
Insider trade positions for Adaptimmune Therapeutics Plc ADR [ADAP]
There are presently around $31.32%, or 31.52%% of ADAP stock, in the hands of institutional investors. The top three institutional holders of ADAP stocks are: MATRIX CAPITAL MANAGEMENT COMPANY, LP with ownership of 38.97 million shares, which is approximately 2.5415%. ECOR1 CAPITAL, LLC, holding 27.4 million shares of the stock with an approximate value of $$26.72 million in ADAP stocks shares; and ECOR1 CAPITAL, LLC, currently with $$16.65 million in ADAP stock with ownership which is approximately 1.1138%.
